InstalabLoading...
InstalabLoading...
If your ceruloplasmin level comes back low, the first question on most clinicians' minds is whether you might have Wilson disease, a genetic condition in which copper accumulates to toxic levels in the liver, brain, and other organs. That is the test's primary clinical purpose. But ceruloplasmin is more than just a Wilson disease marker. It is a protein your liver produces that carries about 95% of the copper in your blood, and it plays a surprisingly important role in iron metabolism, not just copper transport.
The test measures the concentration of ceruloplasmin protein in your blood. A low result suggests your body may not be producing enough of it, which can signal a copper metabolism disorder, liver synthetic failure, or protein loss from other causes. An elevated result usually reflects inflammation, infection, or estrogen-driven changes rather than copper overload. Understanding what is driving your number in either direction is where clinical context becomes essential.
Each ceruloplasmin molecule contains six copper atoms. Its most important job is not actually about copper, though. Ceruloplasmin functions as a ferroxidase, an enzyme that converts iron from one chemical form to another so it can be loaded onto transferrin, the main iron transport protein in blood. Without this step, iron cannot move efficiently through your body and instead accumulates in tissues where it generates damaging chemical reactions.
This iron connection is vividly illustrated by a rare genetic condition called aceruloplasminemia, in which people produce little or no ceruloplasmin. Rather than developing copper problems, they develop iron overload in the brain, pancreas, and liver, leading to neurodegeneration, diabetes, and retinal damage, typically appearing in the fifth or sixth decade of life. Their laboratory profile shows high ferritin, low serum iron, and normal urinary copper, a pattern that looks nothing like Wilson disease despite the shared finding of very low ceruloplasmin.
Ceruloplasmin also exists in a separate form anchored to the surface of brain cells called astrocytes, where it manages iron metabolism locally within the brain. The blood test does not capture this brain-specific form, but its existence helps explain why ceruloplasmin deficiency can cause neurological damage even when circulating copper levels are not the main issue.
Wilson disease is a genetic disorder caused by mutations in the ATP7B gene, which impair the liver's ability to excrete copper into bile. Copper gradually accumulates in the liver and eventually spills into the bloodstream, depositing in the brain, eyes, and other organs. Ceruloplasmin is low in most people with Wilson disease because the same protein machinery that exports copper into bile also loads copper into ceruloplasmin during its production.
However, ceruloplasmin alone is not sufficient to diagnose or rule out Wilson disease. It is a screening test, not a definitive one. A very low level, below about 5 mg/dL, strongly suggests the diagnosis. But the traditional cutoff of 20 mg/dL casts too wide a net. Studies from Hong Kong and Spain have identified lower thresholds of 14 mg/dL and 11.5 mg/dL, respectively, as providing better specificity. In practice, results need to be interpreted alongside other findings: 24-hour urinary copper excretion, a slit-lamp eye exam looking for copper deposits in the cornea (called Kayser-Fleischer rings), liver copper content on biopsy, and ATP7B genetic testing.
Importantly, ceruloplasmin can be normal in someone who has Wilson disease. This is uncommon but does happen, which is why guidelines recommend a multi-test approach rather than relying on any single result.
The populations who benefit most from ceruloplasmin testing are those with unexplained liver disease between the ages of roughly 3 and 55, first-degree relatives of someone diagnosed with Wilson disease, young adults with unexplained movement disorders or psychiatric symptoms, and anyone presenting with acute liver failure accompanied by destruction of red blood cells (a pattern called Coombs-negative hemolytic anemia). A study of ceruloplasmin test utilization found that about 20.8% of tests were ordered in people over age 55, none of whom turned out to have Wilson disease, suggesting meaningful overuse in older populations.
Ceruloplasmin is what is known as an acute-phase reactant, meaning your liver ramps up production in response to inflammation. During an acute inflammatory episode, the gene that codes for ceruloplasmin increases its activity roughly 6 to 10 fold within 24 hours. This means that infections, autoimmune flares, or even active malignancy can push your ceruloplasmin well above normal. In one study, surgical patients with infections had a mean ceruloplasmin of 64.2 mg/dL compared to 35.1 mg/dL in healthy controls.
This acute-phase behavior creates a diagnostic trap. If you have Wilson disease but also happen to have an active infection or inflammatory condition, your ceruloplasmin can rise into the normal range, masking the underlying deficiency. Estrogen has a similar effect: pregnancy, oral contraceptives, and estrogen supplementation can all normalize ceruloplasmin in someone with Wilson disease because the ceruloplasmin gene contains estrogen-responsive elements.
On the low side, many conditions besides Wilson disease can reduce your ceruloplasmin. They fall into a few conceptual groups:
Carriers of a single ATP7B mutation (heterozygous carriers who do not have Wilson disease) can also have mildly reduced ceruloplasmin. Up to 30% of carriers have levels between 15 and 19 mg/dL, which can overlap with the range seen in affected individuals.
Because ceruloplasmin production is driven primarily by liver function, copper availability, inflammatory status, and hormonal milieu, the interventions that move this biomarker are largely medical rather than lifestyle-based.
Treating the underlying condition is the most direct lever. In Wilson disease, copper-chelating medications (which remove excess copper from the body) and zinc therapy (which blocks copper absorption) are the mainstays of treatment, though ceruloplasmin itself may remain low even with successful treatment because the underlying genetic defect in copper loading persists. In acquired copper deficiency from zinc overuse, bariatric surgery, or malabsorption, correcting the copper deficit with supplementation restores ceruloplasmin production.
Estrogen exposure reliably raises ceruloplasmin. If you are taking oral contraceptives or hormone replacement therapy, expect your level to be higher than it would otherwise be. This is not a therapeutic intervention but an important variable to account for when interpreting your result.
Inflammation management matters in both directions. Reducing chronic inflammation (through treatment of infection, autoimmune disease, or malignancy) will lower an elevated ceruloplasmin toward its true baseline. Conversely, if you are being evaluated for Wilson disease during an active inflammatory episode, the result may be unreliable, and retesting when inflammation has resolved is advisable.
There are no well-established dietary or exercise interventions that meaningfully shift ceruloplasmin in healthy individuals. Ensuring adequate dietary copper intake through foods like shellfish, nuts, seeds, and organ meats supports normal production, but in the absence of frank deficiency, additional copper does not raise ceruloplasmin further.